AstraZeneca Praises EPO's Rigorous Patent Process
AstraZeneca, a leading global biopharmaceutical company, recently praised the European Patent Office (EPO) for its rigorous patent examination process. The company, which employs over 94,000 people worldwide and sells its medicines in over 125 countries, held a high-level online zoom meeting with the EPO on 19 September 2025.
The meeting, the 19th of its kind in 2025 and the 100th since the launch of the EPO's Strategic Plan 2023, was led by Mr Scott Alban from AstraZeneca's side. The delegation commended the EPO for providing strong patents that can be used for litigation, highlighting the depth and rigor of the search and examination process. AstraZeneca, which ranks as the EPO's 193rd top applicant with 121 European patent filings, also welcomed the EPO's focus on quality action plans for 2024 and 2025.
Discussions during the meeting centered around accelerating the patent granting process, the use of MyEPO's Shared Area, and the importance of consistency in practice. Mr Alban thanked the EPO for the opportunity to meet and exchange ideas, considering it a critical partner in AstraZeneca's mission. In 2024, AstraZeneca's revenue stood at USD 54.1 billion, with USD 13.6 billion invested in research and development.
AstraZeneca's praise for the EPO's patent examination process underscores the importance of robust intellectual property protection for global pharmaceutical companies. The meeting, part of a series of high-level discussions between the EPO and large applicants, reflects AstraZeneca's commitment to innovation and intellectual property management.
Read also:
- Germany Launches HoLa Project for Megawatt Charging on A2 Motorway
- Wallenius Wilhelmsen Leads Maritime Industry's Push to Net Zero Emissions by 2027
- Transforming Digital Inventories in the Food Industry: A Comprehensive Guide for Food Businesses
- Canada's Transportation Revolution: Hyperloop & Electric Air Taxis by 2026
